The Energy Source Whose Depletion Requires Surgery
Every implantable active medical device, from the cardiac pacemaker whose electrical impulses maintain the heart rhythm of patients with bradycardia to the implantable cardioverter defibrillator whose high-energy shock terminates ventricular fibrillation to the spinal cord stimulator whose continuous low-frequency electrical output modulates chronic pain signals, depends on an implanted power source whose depletion requires either device replacement surgery or device extraction and battery replacement whose procedural complexity and patient risk create the clinical and commercial context that implantable battery longevity determines. A pacemaker whose battery depletes after eight years of implantation requires a replacement procedure whose surgical risk, hospitalisation cost, and patient inconvenience are manageable but represent real clinical events that the device manufacturer and the clinical community have economic and humanitarian motivation to avoid by extending the battery's operational life. A spinal cord stimulator whose power consumption from continuous therapeutic output depletes its battery after three years without the rechargeable capability that premium SCS systems provide requires more frequent replacement procedures whose cumulative surgical exposure over a patient's lifetime creates the medical device longevity problem that implantable battery technology is the most commercially significant factor in resolving.
The implantable medical device battery market, valued at approximately $2.1 billion in 2026 and growing at around six percent annually, encompasses the lithium-iodine, lithium-carbon monofluoride, lithium-manganese dioxide, and lithium-silver vanadium oxide primary battery chemistries that have been the standard power sources for different categories of implantable devices for decades, alongside the lithium-ion rechargeable batteries that have expanded the range of devices that can be recharged transcutaneously without surgical battery access. Integer Holdings, formerly Greatbatch, is the dominant commercial supplier of implantable batteries whose market position reflects its decades as the sole qualified supplier of lithium-iodine batteries for cardiac pacing and its expansion across the full range of implantable device power source chemistries as the device portfolio of its cardiac rhythm management, neuromodulation, vascular, and surgical device customers has diversified.
Integer Holdings and the Qualified Supplier Position
Integer Holdings is the world's largest manufacturer of batteries for implantable medical devices, with its Electrochem brand covering the primary battery chemistries used across cardiac rhythm management, neuromodulation, and other implantable device categories. Its commercial position in implantable batteries reflects the extraordinarily high qualification barrier that implantable device battery supply requires, because the battery's failure during implantation would have immediate life-threatening consequences for the patient in a cardiac or ICD application and clinically significant consequences in neuromodulation and other applications, creating the regulatory scrutiny, clinical validation, and accelerated longevity testing that qualifying a new implantable battery supplier requires from the device manufacturer's perspective. The FDA's scrutiny of implantable battery supply chain changes through the CAPA process that any material component supplier qualification change triggers, combined with the device manufacturer's design validation and reliability testing requirements for any battery supplier change, creates the switching cost that maintains Integer's dominant market position despite the premium pricing that its qualified supplier status supports.
EaglePicher Medical Power, the US implantable battery company that is Integer's primary competitor in certain implantable battery categories, has maintained its competitive position through product differentiation in specific chemistries and device categories. Its lithium-carbon monofluoride batteries for devices whose moderate current drain requirements and long implant duration fit LiCFx's flat discharge curve and energy density advantages over lithium-iodine create the chemistry-specific competition that prevents complete market consolidation around Integer. The development of solid-state implantable batteries whose ceramic electrolyte eliminates the liquid electrolyte safety concern that liquid electrolyte lithium batteries carry in the implanted environment, and whose energy density and cycle life improvements over conventional lithium-ion rechargeable batteries could extend the operational life of rechargeable neurostimulators whose recharge frequency and battery longevity determine patient compliance with the recharging protocol, is the technology frontier that research at leading device companies and academic institutions is pursuing without a clear commercial timeline for deployment in implantable devices.
Wireless Charging and the Rechargeability Revolution
The introduction of transcutaneous wireless charging for implantable device batteries, using inductive coupling between an external charging wand and an implanted receiving coil to transfer energy to the implanted rechargeable battery without surgical access, has transformed the commercial dynamics of the spinal cord stimulator and deep brain stimulator markets by enabling higher-energy therapeutic output without the surgical replacement frequency that primary battery depletion would create. The rechargeable SCS market, in which the Medtronic Intellis, Abbott Proclaim, and Boston Scientific Spectra WaveWriter all offer rechargeable implantable pulse generator options whose transcutaneous charging allows patients to maintain continuous high-energy therapeutic stimulation without battery replacement surgery, has essentially created the device category that would not be commercially viable with primary battery technology whose size constraints at the energy density required for years of continuous stimulation would produce an implant too large for acceptable subcutaneous placement.
Top 10 Companies in Implantable Medical Device Batteries Globally
- Integer Holdings (Electrochem): US implantable medical device component company with Electrochem batteries for cardiac, neuromodulation, and other implantable devices; its dominant market share in qualified implantable battery supply and its decades of lithium-iodine, LiCFx, LiMnO2, and Li-SVO battery manufacturing create the commercial standard-setter in implantable battery supply.
- EaglePicher Medical Power: US implantable battery manufacturer with lithium-carbon monofluoride and other primary battery chemistries for implantable devices; its chemistry-specific differentiation and its qualified supplier position with selected device manufacturers create the primary commercial alternative to Integer in specific implantable battery categories.
- Ilika Technologies: UK solid-state battery company with Stereax solid-state batteries for implantable medical device applications; its ceramic electrolyte solid-state battery whose safety and energy density advantages over liquid electrolyte batteries create the development-stage solid-state implantable battery that future generations of implantable devices could incorporate.
- Cymbet Corporation: US thin-film solid-state battery company with EnerChip solid-state batteries for medical device applications; its thin-film deposition battery manufacturing and its solid-state safety profile create the solid-state battery commercial position in the small-form-factor implantable device market whose miniaturisation requirements favour thin-film energy storage.
- Quallion: US lithium-ion battery company with implantable medical device rechargeable batteries; its medical-grade lithium-ion cells and its device manufacturer qualification programmes create the rechargeable implantable battery supplier whose products serve the growing rechargeable SCS and DBS device market.
- Saft (TotalEnergies): French battery company with lithium primary and rechargeable batteries for medical device applications; its industrial battery manufacturing heritage and its medical device battery product range create the European battery company's implantable device power source commercial position.
- Ultralife Corporation: US battery company with primary lithium batteries for medical device applications; its thin lithium cells and its medical battery quality management systems create the battery supplier for the non-implantable and some implantable medical device power source markets.
- Solid Power: US solid-state battery company with solid-state electrolyte technology applicable to medical devices; its automotive solid-state battery development and its sulphide-based solid-state electrolyte create the technology foundation that medical device solid-state battery adaptation could draw on when the cost and form factor requirements of implantable applications are met.
- EPS Bio: Israeli medical technology company with implantable power management including energy harvesting from physiological sources; its piezoelectric cardiac motion energy harvesting research and its implantable device power management create the emerging field of biologically-powered implantable devices that could eventually reduce or eliminate the battery longevity constraint on some device categories.
- BIOTRONIK: German cardiac device company with cardiac pacemaker and ICD battery technology developed in-house alongside its device manufacturing; its internal battery development capability creates the device manufacturer's perspective on implantable battery performance requirements whose understanding of clinical use patterns and device failure modes informs the battery engineering that commercial battery suppliers must ultimately satisfy.